Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Doxil, PLD, Caelyx
Pegylated Liposomal Doxorubicin+ SL-172154 · 1 trial · 7 indications
Number of participants with treatment emergent adverse events from dose escalation and expansion cohorts
Based on review of all data, including safety, tolerability, PK, antitumor activity, and PD effects"
| Arm | Type | Description |
|---|---|---|
| Pegylated Liposomal Doxorubicin + SL-172154 (SIRPα-Fc-CD40L) | EXPERIMENTAL | Pegylated Liposomal Doxorubicin (PLD) will be administered via intravenous administration + SL-172154 (SIRPα-Fc-CD40L) will be administered via intravenous administration. |
| Mirvetuximab + SL-172154 (SIRPα-Fc-CD40L) | EXPERIMENTAL | Mirvetuximab (MIRV) will be administered via intravenous administration + SL-172154 (SIRPα-Fc-CD40L) will be administered via intravenous administration |
| Name | Type | Description |
|---|---|---|
| Pegylated Liposomal Doxorubicin + SL-172154 | DRUG | The investigational product, SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc. |
| Mirvetuximab + SL-172154 | DRUG | The investigational product, SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc. |
Inclusion Criteria: 1. Subject has voluntarily agreed to participate by giving written informed consent in accordance with ICH/GCP guidelines and applicable local regulations. 2. Age ≥18 years 3. \[PLD Cohort\] Subject has a histologically confirmed diagnosis of high grade epithelial ovarian cancer...
Pegylated Liposomal Doxorubicin + SL-172154 is being studied in platinum-resistant ovarian cancer, including related platinum-resistant fallopian tube and primary peritoneal cancers. It combines pegylated liposomal doxorubicin, a chemotherapy agent, with SL-172154, an investigational immunotherapy. The regimen is given to adult women with these platinum-resistant gynecologic cancers.
SL-172154 targets F8, an exogenous protein target. Pegylated liposomal doxorubicin is a liposomal formulation of the chemotherapy drug doxorubicin. The combination pairs this chemotherapy backbone with the F8-directed investigational agent in platinum-resistant ovarian cancer.
Shattuck Labs, Inc. (ticker STTK) is developing Pegylated Liposomal Doxorubicin + SL-172154. The company is the sponsor of the clinical program evaluating this combination in platinum-resistant ovarian cancer and related gynecologic cancers.
Pegylated Liposomal Doxorubicin + SL-172154 is in Phase 1 development. It is investigational and has not been approved by the FDA. The program has completed one Phase 1b trial in platinum-resistant ovarian cancer and related conditions, with no active trials currently listed.
Pegylated Liposomal Doxorubicin + SL-172154 was evaluated in the Phase 1b trial NCT05483933, titled a study of SL-172154 administered with combination agents in subjects with ovarian cancers. That trial enrolled 86 participants across the United States, Canada, Spain, and the United Kingdom and is now completed.